Engineering teams meticulously document component details but often fail to apply the same rigor to assembly specifications. This oversight becomes a major source of failure, especially when transitioning from pilot lines to high-volume manufacturing.

Despite numerous announcements of new US pharmaceutical factories, tangible production capacity is not immediate. Building a highly automated facility, procuring machinery, and integrating it takes 18-24 months alone. A realistic timeline for significant output from these new investments is three to five years.

Atomic Industries is scaling its manufacturing operations by creating a bifurcated factory system. Its first facility is dedicated solely to designing and creating molds. These molds are then shipped to a second, larger facility focused exclusively on high-volume part production, optimizing the workflow for both complex tooling and mass manufacturing.

The reality of hospital value analysis committees means product adoption takes years. Entrepreneurs must build this lengthy timeline into financial models and fundraising to ensure survival, rather than projecting rapid uptake.

Instead of immediately scaling up the manufacturing process between clinical Phase 1 and 2, it is strategically better to produce more batches using the established Phase 1 process. This approach builds critical knowledge about process parameters and CQAs through repetition and increased clinical exposure.

Instead of rushing to the clinic, MRM Health deliberately slowed down for five years to develop its CORAL platform. This end-to-end platform solves strain selection, single-process manufacturing, and delivery upfront, preventing the CMC (Chemistry, Manufacturing, and Controls) issues that plagued earlier microbiome companies.

To ensure a smooth transition from development to production, an operations or manufacturing SME must be part of the design process from the start. Otherwise, products are developed without manufacturability in mind, leading to expensive, reactive fixes and subjective quality control during scale-up.

A 'healthy tension' exists between research teams, who want to continually iterate on a therapy's design, and manufacturing teams, who need a finalized process to scale production for trials. Knowing precisely when to 'lock down' the design is a critical, yet difficult, decision point for successful commercialization.

Business growth isn't linear. Scaling up introduces novel challenges in complexity, cost, and logistics that were non-existent at a smaller size. For example, doubling manufacturing capacity creates new shipping and specialized hiring problems that leadership must anticipate and solve.